Private hospitals across Madhya Pradesh plan to stop admitting Ayushman Bharat patients from 8 October over pending dues and a new NABH condition on empanelment, the Free Press Journal reports. For diagnostic labs, this is not a hospital-sector story to be read and set aside. Labs that run outsourced tests, referral work and corporate panels for those hospitals carry the same cashflow strain one step removed, and usually without a seat at the negotiation.
When a lab processes an investigation for an empanelled hospital, the lab's debtor is the hospital, not the scheme. The scheme package rate already includes investigations, so the hospital recovers the lab's charge only when the package is settled. If settlement stretches to 90 or 120 days, the lab has effectively extended working capital to a payer it never signed with and cannot follow up with.
A stoppage changes the shape of the problem rather than solving it. Admissions pause, so the histopathology, special chemistry and advanced molecular work that came from those wards stops arriving within days. Reagent rate contracts, machine AMC obligations, phlebotomist salaries and courier runs do not pause with it. Cost per test rises because the denominator fell, and the old receivable is still outstanding while new billing has dried up.
The first question is simple and most labs cannot answer it in under an hour: what share of monthly B2B billing comes from partners whose own cash arrives mainly from one government scheme? Until that number exists, every payer dispute in the news is guesswork about the lab's own exposure.
Three figures make the exposure visible. First, revenue share by partner for the trailing six months, with the top five listed separately. Second, the share of each partner's volume that is scheme-funded, which the hospital's billing team will usually confirm if asked directly. Third, days sales outstanding calculated per partner rather than across the whole receivable, because one slow hospital inside a healthy average is exactly the case that hurts.
Plain arithmetic sharpens it. A lab billing Rs 18 lakh a month in B2B work, with three scheme-heavy hospitals contributing Rs 7 lakh of that, is looking at roughly Rs 10 lakh of deferred billing across a six-week stoppage, on top of whatever is already ageing. That is a reagent order and a month of salaries, not a rounding difference.
Test mix matters as much as rupee value. Routine haematology lost from one partner is replaceable from walk-in and home-collection demand. A tissue processing or hormone assay line that ran mainly on one hospital's inpatient load is not, and its per-test cost moves sharply once daily volume halves. Labs running several centres should see this split centre-wise, since the exposure is rarely spread evenly across outlets.
Most lab-to-hospital credit terms were set when the relationship started and never revisited. A partner whose receivables are tied up in a payer dispute is a different credit risk from the same partner two years ago, and the terms should say so. That means a stated credit limit per partner, a defined action when the limit is crossed, and advance payment on high-value outsourced tests rather than an open-ended tab.
This only works if the rate card lives in the billing engine rather than in a signed PDF in someone's drawer. Rates per partner, a prepaid rate distinct from a credit rate, and revisions dated from the day they take effect, all of it has to be enforced at the point of billing, otherwise the front desk keeps raising bills at terms nobody intends. Labs that handle this well treat a term change as a system change, not a circular.
Equally, the lab should not discover a partner's trouble from a newspaper. A partner receivable crossing its ageing bucket, or a sudden drop in daily sample count from a regular hospital, is an earlier signal than any announcement. Both are already in the lab's own data; they just need to be reviewed weekly by someone with authority to put a partner on hold.
The NABH condition in the Madhya Pradesh dispute points at something labs should read closely. Accreditation is being used as an empanelment gate rather than a quality badge, and the lab equivalent is NABL. Scheme panels, insurers and corporate contracts increasingly ask for accreditation status before rates are discussed, which makes it a commercial requirement with a revenue consequence attached.
Accreditation readiness is a daily record or it is a scramble. The evidence an assessor asks for is the same evidence a lab needs to run well: internal quality control plotted and reviewed, equipment calibration and maintenance history, sample acceptance and rejection logs with reasons, turnaround time measured from collection rather than from registration, and a clear authorisation trail showing who released each report. Reconstructing twelve months of that in three weeks is where labs lose both the assessment and the staff week.
Direct instrument interfacing helps more than it appears to. Results that move from analyser to report without manual transcription remove a whole class of correction and a whole class of audit question, and they make turnaround time measurable rather than estimated. Quality control that is plotted continuously, instead of filed monthly, catches drift while it is still cheap to fix.
A hospital that stops scheme admissions does not stop treating patients. Outpatient volume, insurance cases and cash work continue, and some of the deferred inpatient demand reappears as outpatient investigation and home collection. Labs that stay close through a dispute usually keep the partner afterwards; labs that respond only by stopping credit tend to lose both the receivable and the relationship.
What holds the relationship together during a disruption is operational, not commercial. The partner's team should be able to see sample status, download reports and check pending items without calling the lab, because status calls multiply exactly when both sides are under pressure. Outsourced samples sent to a partner lab need end-to-end tracking, since a sample that cannot be located is a dispute waiting to be filed. Turnaround performance should be reportable with timestamps when a partner questions it, which is also the evidence base for any rate conversation later.
The same discipline opens the alternative channels. A lab with partner pricing, tracking and reporting under control can add a franchisee, a collection centre or a corporate panel without rebuilding its masters each time, which is how concentration gets reduced rather than merely monitored.
Payer disputes will keep arriving, and labs will keep learning about them late. The practical defence is measurement at partner level and terms that can be changed in the system the same day they are agreed. In Labzapp, differential pricing per partner holds a separate rate card for every hospital, corporate and franchisee, including distinct prepaid and credit rates, so a term change is enforced at billing instead of being remembered by the front desk. Multi-centre financials show revenue, receivable ageing and test mix per partner and per centre, which is what turns concentration from a feeling into a reviewable number. Referral-doctor and corporate-partner portals give partners their own status and report access, cutting the inbound call load during exactly the weeks when volume and tempers are both unstable, while TAT reporting keeps the performance record defensible for accreditation and for rate talks alike.
See how Labzapp handles this, book a 30-min demo.
See how Healzapp, Labzapp and EReazy fit your speciality in a free 30-minute demo.
Book a Free Demo